BRAF and neoplasm: While the combined oncogenic pathway signature correctly predicted the presence of a mutation in KRAS or BRAF known mutation carriers, interestingly, more than two fold of the tumours that had no oncogenic mutations in BRAF and KRAS were also classified as oncogenic based on their gene expression signatures indicating that many KRAS and BRAF wild type patients share the same phenotype of an activated EGFR pathway as the patients with at least one activating mutation.